Effect study of Exenatide on patients with polycystic ovary syndrome and type 2 diabetes in plateau area

范晓霞,姚勇利,胡耀嘉,范培云,罗玮,王淑琼,魏兰,宋康,林丽君
DOI: https://doi.org/10.3969/j.issn.1006-6187.2017.03.010
2017-01-01
Abstract:Objective To investigate the efficacy and safety of Exenatide in patients type 2 diabetes (T2DM ) and polycystic ovary syndrome (PCOS ) in plateau area. Methods A total of 75 T2DM patients with PCOS from plateau area admitted in our hospital were enrolled in this study and divided into two groups :control group (Con ) and Exenatide treatment group. The Con group was treated with Metformin 500 mg ,3/d ,and the Exenatide treatment group was given subcutaneous injection of Exenatide 5 μg ,1 h before breakfast and dinner ,and increased to 10 μg one month later ,and followed up for three months. FPG ,FIns ,2 hPG ,2 hIns ,HbA1 c ,body weight ,blood lipid ,and sex hormones were tested at baseline and after treatment. BMI and insulin resistance index (HOMA-IR) were also calculated. Hypoglycemia and other adverse events during follow up were recorded. Results BMI ,HbA1c ,FPG , 2 hPG ,TG ,TC ,LDL-C and HOMA-IR were decreased after treatment ,and all these above indexes were lower in Exenatide treatment group than in Con group (P<0.05). Serum luteinizing hormone (LH) and testosterone (T) were decreased after treatment (P<0.05). There were no hypoglycemia or other severe adverse events in either groups. Conclusion Exenatide can effectively control blood glucose in patients with T2DM and PCOS in plateau area ,and also lower BMI ,improve blood lipid and hyperandrogenemia.
What problem does this paper attempt to address?